socalTECH

JULY 24, 2017

San Diego-based eFFECTOR Therapeutics , a developer of treatments for cancer, has raised $38.6M The funding was led by Pfizer Venture Investments (PVI), and also included Alexandria Venture Investments, along with U.S. in a Series C funding round, the company announced this morning. in total funding. READ MORE>>.

Study 113

Study San Diego Invest Funding 113

Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

MAY 19, 2020

Amplyx Pharmaceuticals has completed enrollment in one mid-stage trial of its lead drug candidate, a new kind of antifungal treatment, and has finished treating the first patients in two more such studies.

San Diego 114

San Diego Funding Study Company 114

SoCal Tech Calendar

MAY 4, 2010

Monday, May 10, 2010 -- Power of Angel Investing. San Diego Tech Coast Angels. This full-day seminar provides an overview of the angel investing process including the details of finding, evaluating, and structuring deals and developing angel-entrepreneur relationships that lead to success.

Invest 100

Invest Tech Coast Angels Angel Case Study 100

socalTECH

SEPTEMBER 12, 2018

San Diego-based Epic Sciences , which is developing technology around personalization of cancer treatment and management, has raised $52M more in a Series E funding, the company's lead investor said this morning. Epic has now raised more than $137.5M RUSNANO, and VI Ventures. READ MORE>>.

Artificial Inteligence 100

Artificial Inteligence San Diego Study Invest 100

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

Xconomy

OCTOBER 1, 2018

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

FEBRUARY 15, 2017

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64

UCSD Press San Diego Class 64

socalTECH

NOVEMBER 11, 2010

San Diego-based Aires Pharmaceuticals , a developer of treatments for pulmonary arterial hypertension, said this morning that it has raised $20M in a Series B funding round. The round was led by MPM Capital, and also included prior investor ProQuest Investments. MPM's Dr. William Greene joins the board as part of the funding.

San Diego 154

San Diego Venture Capital Study Capital 154

socalTECH

FEBRUARY 9, 2011

In fact, a recent study released by Ernst & Young found that there were eight companies in Southern California, out of 22 total in California, who were lined up for an IPO in Q4.

Southern California 200

Southern California Westlake Village Woodland Hills Beverly Hills 200

Xconomy

DECEMBER 7, 2017

Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

Xconomy

AUGUST 17, 2016

Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China. Histogen claims that HSC triggers stem cells in the scalp to form hair.

Invest 40

Invest San Diego Journal Technical Review 40

Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. Those concerns are shared by the public. But they did not view tech companies as trustworthy stewards.

PMI 40

PMI Study Google Research 40

Xconomy

AUGUST 17, 2016

San Diego’s Avelas Biosciences , founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million Series C round of venture funding. and San Diego’s Avalon Ventures. Carmine Stengone.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

FEBRUARY 14, 2020

Post-marketing studies aim to identify side effects not observed in the first three phases of testing. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). But the post-marketing study revealed a higher incidence of.

Study 77

Study Marketing San Diego Blogging 77

Xconomy

APRIL 22, 2020

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138

Class Study Research Report 138

Xconomy

JULY 27, 2018

Eisai and partner Biogen released the highly anticipated details of an Alzheimer’s disease study they had already deemed positive, after an initial failure. In one sense, the study was the success they have claimed. A high dose of the drug appeared to have a positive impact on patients, compared to placebo.

Study 64

Study Invest San Diego Venture Capital 64

Xconomy

MARCH 27, 2020

Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. The coronavirus pandemic has made it nearly impossible.

Study 95

Study Resource Sites San Diego 95

Xconomy

AUGUST 22, 2016

In downtown San Diego, a private real estate company best known for its master-planned communities in suburban Southern California has posed some existential questions for regional tech hubs looking to build their own startup ecosystems. 101 West Broadway tower in downtown San Diego. John “J.T.”

Develop 40

Develop Development San Diego Startup 40

Xconomy

FEBRUARY 28, 2020

Making changes in the midst of the study was a no-no. Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient.

News 89

News Design Study Examples 89

Xconomy

MAY 22, 2020

But Phase 1 clinical trials are small, and it’s unknown whether those early results can be replicated in larger studies. No major safety problems were reported and there were some indications that the injections elicited antibodies. Furthermore, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 80

Study Report San Diego Blogging 80

Xconomy

AUGUST 14, 2020

Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work.

Study 63

Study Course Report Company 63

Xconomy

SEPTEMBER 6, 2019

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

FEBRUARY 22, 2019

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86

News Study Report San Diego 86

Xconomy

JANUARY 9, 2019

The Boston company, which counts diabetes drug giants Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) among its investors and partners, says the capital will support Phase 3 studies of its device this year, and if all goes well, an application for FDA approval. Beta Bionics’s device is designed to mimic the role of.

Study 87

Study Design Capital Startup 87

Xconomy

JUNE 13, 2019

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78

Tool Study Research Startup 78

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

DECEMBER 21, 2016

After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company. [Editor’s note: Alex Lash and Frank Vinluan contributed to this report.]

Study 40

Study Report Research Invest 40

socalTECH

FEBRUARY 3, 2012

Right now, we have developers in Belgium, Texas, New York, San Diego, Florida, and in the Bahamas. Jonathan LaCour: I studied finance in law school, and did lots of structured finance and investments. It was a videogame startup, but I had a bit of a creative difference with the CEO.

Startup 217

Startup Mobile Venture Capital Resource 217

Xconomy

JANUARY 11, 2017

A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. billion invested in 198 deals in 2015, according to EdSurge. education tech companies totaled $1.03 billion (across 138 deals) in 2016. Those numbers are down from the $1.45

Funding 40

Funding Education Venture Capital Study 40

socalTECH

AUGUST 2, 2013

We really started to study the current generation of smartphones and what people do with them. Phil Kelly: Before Yapert, I was angel investing. Fortunately, in San Diego, we''re able to attract some really good people to work on this. Phil Kelly: It''s kind of interesting. Your background was in telecom, wasn''t it?

Mobile 159

Mobile Startup Entertainment Tech Coast Angels 159

socalTECH

OCTOBER 19, 2016

For a number ofyears, as a venture capitalists, I looked and led Maveron's investments in health and wellness. That's because we'll already have made the investment in your baseline data. In 2014, we did an IRB approved study when I was doing this for 30 to 40 percent of my time, where I learned three things. Why is that?

Coach 100

Coach Startup Study Venture Capital 100

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. After the deals, we’ll move on to data. There were plenty of policy and drug-price headlines, Read more » Reprints | Share:

Study 55

Study Pricing Conference Marketing 55

Xconomy

AUGUST 1, 2016

Ionis (NASDAQ: IONS ) and its partner, Cambridge, MA-based Biogen (NASDAQ: BIIB ), this morning reported an interim look at an ongoing Phase 3 study of nusinersen—an RNA-based drug meant to help treat patients with SMA. Ionis will complete the ongoing Phase 3 studies before transitioning everything to Biogen.

Study 40

Study Research Statistics Help 40

Both Sides of the Table

APRIL 13, 2011

I owe ya’ a 20 minute call (or in person next time I’m in San Diego). I decided well if I am going to be investing in this stuff at least I need to understand what it’s like to have a blog, to be generating content, and it was quite interesting at the very, very beginning.“. we are not going to invest.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

socalTECH

APRIL 3, 2012

For San Diego-based Mob Science (www.mobscience.com), an injection of cash, some key advisors--and a deal with Zynga. We approached them, explained to them what the opportunity was, and also approached them about investment. What does it take to take a social gaming firm to the next level? That's a really critical piece.

IP 217

IP PHP Design Startup 217